Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-6696-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Syk Monoclonal Antibody (4D10.1), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: This 4D10.1 monoclonal antibody recognizes human Syk, a 72-kDa member of the Syk/ZAP-70 family of non-receptor protein tyrosine kinases. Syk is expressed most highly in B cells, with lower expression in immature thymocytes, mast cells, and platelets. Syk can also be detected in fibroblasts, epithelial cells, hepatocytes, endothelial cells, and neuronal cells. This protein is a major component of signaling cascades downstream of the B and T cell antigen receptors and plays an essential role in lymphocyte development. Upon recruitment to immunoreceptor tyrosine-based activation motifs (ITAMs) on the antigen receptors, Syk is activated by phosphorylation on multiple tyrosines. Once activated, Syk phosphorylates proteins such as phospholipase C gamma and BLNK/SLP-65. Finally, abnormal Syk expression has been linked to tumor cell migration and invasion in several cancers.
- Antibody clone number
- 4D10.1
- Concentration
- 0.5 mg/mL
Submitted references Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination.
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
Syk and pTyr'd: Signaling through the B cell antigen receptor.
Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck.
Pre-T cell receptor signals are responsible for the down-regulation of Syk protein tyrosine kinase expression.
The Syk protein tyrosine kinase can function independently of CD45 or Lck in T cell antigen receptor signaling.
Woods E, Zaiatz-Bittencourt V, Bannan C, Bergin C, Finlay DK, Hoffmann M, Brown A, Turner B, Makvandi-Nejad S, Vassilev V, Capone S, Folgori A, Hanke T, Barnes E, Dorrell L, Gardiner CM, PEACHI Consortium
NPJ vaccines 2021 Sep 28;6(1):117
NPJ vaccines 2021 Sep 28;6(1):117
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P, McCullar V, Howard P, Sarhan D, Taras E, Schlums H, Abbot S, Shoemaker D, Bryceson YT, Blazar BR, Wolchko S, Cooley S, Miller JS
Cancer research 2017 Oct 15;77(20):5664-5675
Cancer research 2017 Oct 15;77(20):5664-5675
Syk and pTyr'd: Signaling through the B cell antigen receptor.
Geahlen RL
Biochimica et biophysica acta 2009 Jul;1793(7):1115-27
Biochimica et biophysica acta 2009 Jul;1793(7):1115-27
Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck.
Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, Rhŷs-Evans P, O-charoenrat P, Eccles S
Cancer research 2007 Aug 15;67(16):7907-16
Cancer research 2007 Aug 15;67(16):7907-16
Pre-T cell receptor signals are responsible for the down-regulation of Syk protein tyrosine kinase expression.
Chu DH, van Oers NS, Malissen M, Harris J, Elder M, Weiss A
Journal of immunology (Baltimore, Md. : 1950) 1999 Sep 1;163(5):2610-20
Journal of immunology (Baltimore, Md. : 1950) 1999 Sep 1;163(5):2610-20
The Syk protein tyrosine kinase can function independently of CD45 or Lck in T cell antigen receptor signaling.
Chu DH, Spits H, Peyron JF, Rowley RB, Bolen JB, Weiss A
The EMBO journal 1996 Nov 15;15(22):6251-61
The EMBO journal 1996 Nov 15;15(22):6251-61
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoblotting of reduced Ramos cell lysate with 5 µg/mL of Anti-Human Syk antibody. Bands were visualized using Anti-Mouse IgG HRP.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 4 HCMV impacts on functional and metabolic responses of CD56 dim NK cell subsets post vaccination. Summary of canonical and adaptive CD56 dim NK cells responses at baseline and post-priming vaccination (Day 0, Day 7 and Day 28). Canonical (FcepsilonRgamma1+Syk+) or adaptive (FcepsilonRgamma1+Syk-, FcepsilonRgamma1-Syk+ and FcepsilonRgamma1-Syk-) cells were analysed as indicated for a ex vivo frequencies of NK subsets, b frequency of pS6+, c IFNgamma+ and d IFNgamma MFI in response to IL-12/IL-15 stimulation after vaccination ( n = 4). e Summary of post-priming Mitotracker and f ATP5B MFI in canonical and adaptive CD56 dim NK cells at baseline and Days 7 and 28 ( n = 4). Error bars show SEM. a , e , f Samples were compared by mixed-model with Bonferroni post hoc test. b - d Samples were compared by two-way ANOVA with Sidek's post hoc test. n.s. not significant.